Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN del STK11 del |
| Therapy | Buparlisib |
| Indication/Tumor Type | endometrial carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN del STK11 del | endometrial carcinoma | predicted - sensitive | Buparlisib | Preclinical | Actionable | In a preclinical study, Buparlisib (BKM120) monotherapy resulted in stable disease in a STK11 and PTEN double knock-out mouse model of endometrial carcinoma (PMID: 28945226). | 28945226 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28945226) | PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. | Full reference... |